1. Home
  2. Product Information
  3. Anidulafungin

Product Information

Anidulafungin

Class Echinocandin antifungal
Mechanism of Action 1,3-ß-D-glucan Synthesis Inhibitor
Target Indication Candida Infections
Overseas Development Status Marketed (Eraxis)
Portfolio for development and marketing rights in Japan
Product Summary Anidulafungin is based on a different mechanism from existing polyene or azole antifungals and is a treatment for invasive echinocandin fungal infections. This product is already marketed in the United States, Great Britain and Canada and hasexcellent clinical efficacy. Because it does not have safety issues associated with the drug interactions characteristic of the azole medications, it has been judged to be an easy-to-use drug. Existing echinocandida antifungals are the drug of choice for treating candida infections and are recommended in guidelines for invasive fungal infection treatment.

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics